ADMA Biologics, Inc. (ADMA) stock
ADMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 16/3037% below fair value
$13.24+0.05 (+0.38%)
Close on Nov 12, 2026Market cap $2.97BP/E 17.2Yield –
ADMA Biologics operating margin
Operating margin is operating income as a percentage of revenue.
ADMA Biologics's operating margin for the twelve months ending Sep 30, 2026 was 46.5%. For fiscal 2025 it was 37.5%, against 32.6% the year before. The highest annual figure on record is 37.5% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 37.5% | +4.9 |
| FY2024 | Dec 31, 2024 | 32.6% | +24.2 |
| FY2023 | Dec 31, 2023 | 8.4% | +33.9 |
| FY2022 | Dec 31, 2022 | -25.5% | +46.6 |
| FY2021 | Dec 31, 2021 | -72.1% | +81.6 |
| FY2020 | Dec 31, 2020 | -153.8% | −12.6 |
| FY2019 | Dec 31, 2019 | -141.1% | +213.8 |
| FY2018 | Dec 31, 2018 | -354.9% | −182.2 |
| FY2017 | Dec 31, 2017 | -172.7% | −10.2 |
| FY2016 | Dec 31, 2016 | -162.6% | +53.6 |
| FY2015 | Dec 31, 2015 | -216.1% | +54.6 |
| FY2014 | Dec 31, 2014 | -270.8% | +219.6 |
| FY2013 | Dec 31, 2013 | -490.4% | +217.0 |
| FY2012 | Dec 31, 2012 | -707.4% | −99.9 |
| FY2011 | Dec 31, 2011 | -607.5% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 48.0% | +10.0 |
| Q2 FY2026 | Jun 30, 2026 | 42.2% | +7.1 |
| Q1 FY2026 | Mar 31, 2026 | 50.9% | +20.5 |
| Q4 FY2025 | Dec 31, 2025 | 45.1% | +12.5 |
| Q3 FY2025 | Sep 30, 2025 | 38.0% | +4.9 |
| Q2 FY2025 | Jun 30, 2025 | 35.1% | −1.5 |
| Q1 FY2025 | Mar 31, 2025 | 30.4% | +3.7 |
| Q4 FY2024 | Dec 31, 2024 | 32.6% | +13.3 |
| Q3 FY2024 | Sep 30, 2024 | 33.1% | +20.2 |
| Q2 FY2024 | Jun 30, 2024 | 36.6% | +37.4 |
| Q1 FY2024 | Mar 31, 2024 | 26.7% | +28.1 |
| Q4 FY2023 | Dec 31, 2023 | 19.3% | +31.4 |
| Q3 FY2023 | Sep 30, 2023 | 12.9% | +35.6 |
| Q2 FY2023 | Jun 30, 2023 | -0.8% | +26.3 |
| Q1 FY2023 | Mar 31, 2023 | -1.4% | +49.5 |
| Q4 FY2022 | Dec 31, 2022 | -12.1% | +37.9 |
| Q3 FY2022 | Sep 30, 2022 | -22.7% | +47.1 |
| Q2 FY2022 | Jun 30, 2022 | -27.1% | +60.3 |
| Q1 FY2022 | Mar 31, 2022 | -50.9% | +43.6 |
| Q4 FY2021 | Dec 31, 2021 | -50.0% | +73.4 |
| Q3 FY2021 | Sep 30, 2021 | -69.8% | +64.5 |
| Q2 FY2021 | Jun 30, 2021 | -87.4% | +132.5 |
| Q1 FY2021 | Mar 31, 2021 | -94.5% | +69.9 |
| Q4 FY2020 | Dec 31, 2020 | -123.4% | −58.4 |
| Q3 FY2020 | Sep 30, 2020 | -134.3% | −9.0 |
| Q2 FY2020 | Jun 30, 2020 | -219.9% | −47.1 |
| Q1 FY2020 | Mar 31, 2020 | -164.4% | +209.9 |
| Q4 FY2019 | Dec 31, 2019 | -65.0% | +342.9 |
| Q3 FY2019 | Sep 30, 2019 | -125.3% | +200.7 |
| Q2 FY2019 | Jun 30, 2019 | -172.8% | +115.3 |
| Q1 FY2019 | Mar 31, 2019 | -374.3% | +34.7 |
| Q4 FY2018 | Dec 31, 2018 | -407.9% | −320.1 |
| Q3 FY2018 | Sep 30, 2018 | -326.0% | −20.9 |
| Q2 FY2018 | Jun 30, 2018 | -288.1% | −41.0 |
| Q1 FY2018 | Mar 31, 2018 | -409.0% | −183.2 |
| Q4 FY2017 | Dec 31, 2017 | -87.8% | +30.7 |
| Q3 FY2017 | Sep 30, 2017 | -305.1% | – |
| Q2 FY2017 | Jun 30, 2017 | -247.2% | – |
| Q1 FY2017 | Mar 31, 2017 | -225.8% | – |
| Q4 FY2016 | Dec 31, 2016 | -118.5% | – |
See a number that looks wrong?